Innate Pharma S.A.

$1.75 USD

-$0.03 (-1.41%)

Volume: 10.42K
Average Volume: 68.57K
Market Capitalization: $164.33M
P/E Ratio: -2.74
Dividend Yield: 0.00%
Price Target: $3.50

Year High: $2.63
Year Low: $1.17
Day High: —
Day Low: —
Payout Ratio: $0.00
Current Ratio: $1.27

Price Target and Rating

Average Stock Price Forecast	$3.50
High Stock Price Forecast	$5.00
Low Stock Price Forecast	$2.00
Forecast Upside/Downside	-50.00%
Consensus Rating	Sell
Rating Score(0-5)	2
Research Coverage	6 Analysts

Profitability

EPS (Most Recent Fiscal Year)	-$0.53
Trailing P/E Ratio	-2.74
PEG Ratio	-0.28
P/E Growth	-0.28
Net Income	-$49.18M
Net Margin	-1764.51%
Pretax Margin	-1987.15%
Return on Equity	593.93%
Return on Assets	-78.41%

Financials Score

AltmanZ Score	-13.80
Piotroski Score	2.00
Working Capital	10.06M
Total Assets	62.69M
Ebit	-105.71M
Market Cap	147.45M
Total Liabilities	84.39M

Poll Results

About Innate Pharma S.A. (NASDAQ:IPHA) Stock

Innate Pharma S.A. is a biotechnology firm, founded in 1999 and headquartered in Marseille, France, that specializes in the discovery, development, and market introduction of therapeutic antibodies. The company primarily targets oncology indications across France and internationally, with some programs also addressing inflammatory diseases and viral infections. Its clinical-stage pipeline features several key assets: Lacutamab (IPH4102): An anti-KIR3DL2 antibody undergoing Phase II trials for cutaneous T-cell and peripheral T-cell lymphoma, and also for refractory Sézary syndrome. Monalizumab: An immune checkpoint inhibitor currently in Phase III clinical trials for various advanced solid tumors, including colorectal, lung, and head and neck cancers. Avdoralimab (IPH5401): A monoclonal ant ... ibody designed to block C5a binding to C5aR1, which is in Phase II development for COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory conditions. IPH5201: A blocking antibody in Phase I trials, focused on the CD39 immunosuppressive pathway. IPH5301: An anti-CD73 antibody developed to enhance anti-tumor immunity by targeting the immunosuppressive adenosine pathway. IPH6101: An NKp46-based NK cell engager being evaluated for the generation of up to two bispecific NK cell engagers. Innate Pharma also maintains an active preclinical pipeline, including IPH43 (an anti-MICA/B antibody drug conjugate), an Anti-Siglec-9 antibody program, IPH65 (a proprietary tetraspecific antibody), IPH25 (a checkpoint inhibitor), and the IPH62 and IPH64 programs. The company has established strategic licensing and collaboration agreements with major industry players such as AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech, alongside a co-development and license agreement with MedImmune Limited.

Outcome of Innate Pharma's 2026 Annual General Meeting

2026-05-22 01:00:00

MARSEILLE, France--(BUSINESS WIRE)--Outcome of Innate Pharma's 2026 Annual General Meeting.

B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic

2026-05-18 14:22:00

/PRNewswire/ -- USA News Group News Commentary - For more than two decades, B7-H3 sat on the shortlist of theoretically perfect cancer drug targets that nobody

Innate Pharma Q1 Earnings Call Highlights

2026-05-13 12:07:58

Innate Pharma NASDAQ: IPHA said its first-quarter 2026 business update centered on three priority clinical assets: lacutamab in cutaneous T-cell lymphoma, the Nectin-4 antibody-drug conjugate IPH4502 in advanced solid tumors, and the AstraZeneca-partnered monalizumab program in non-small cell lung cancer.

Innate Pharma Reports First Quarter 2026 Business Update and Financial Results

2026-05-13 01:00:00

MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its business update and consolidated financial results for the quarter ending March 31, 2026. “We have continued to make solid progress across our priority clinical assets during the first quarter. We are approaching completion of enrollment in the Phase 1 dose escalation and backfill cohorts for IPH4502. In parallel, we have advanced the negotiati.

Number of Shares and Voting Rights of Innate Pharma as of April 16, 2026

2026-05-12 01:00:00

MARSEILLE, France--(BUSINESS WIRE)--Number of shares and voting rights of Innate Pharma as of April 16, 2026.

Innate Pharma Announces Conference Call and Webcast for Q1 2026 Business Update

2026-05-06 01:00:00

MARSEILLE, France--(BUSINESS WIRE)---- $Innate #Biotech--Innate Pharma announces conference call and webcast for Q1 2026 Business Update.

Innate Pharma to Participate in the D. Boral Capital Global Conference

2026-04-23 01:00:00

MARSEILLE, France--(BUSINESS WIRE)-- #Biotech--Innate Pharma to participate in the D. Boral Capital Global Conference.

Frequently Asked Questions

What is the current Innate Pharma S.A. (IPHA) stock price?: Innate Pharma S.A.(NASDAQ:IPHA) stock price is $1.75 in the last trading session. During the trading session, IPHA stock reached the peak price of $2.63 while $1.17 was the lowest point it dropped to. The percentage change in IPHA stock occurred in the recent session was --1.41% while the dollar amount for the price change in IPHA stock was -$0.03.
IPHA's industry and sector of operation?: The NASDAQ listed IPHA is part of Biotechnology industry that operates in the broader Healthcare sector.
Who are the executives of IPHA?: Frederic Lombard | Senior Vice President & Chief Financial Officer
Stephanie Cornen | Vice President of Investor Relations, Communication & Commercial Strategy
Jonathan E. Dickinson | Chief Executive Officer & Director
Yannis Morel | Executive Vice President & Chief Operating Officer
Marc Bonneville | Founder
How many employees does IPHA have?: Number of IPHA employees currently stands at 163. IPHA operates from 117, Avenue de Luminy, Marseille, PA 13009, FR.

Link for IPHA official website?: Official Website of IPHA is: https://www.innate-pharma.com
How do I contact IPHA?: IPHA could be contacted at phone #33 4 30 30 30 30 and can also be accessed through its website. IPHA operates from 117, Avenue de Luminy, Marseille, PA 13009, FR.
How many shares of IPHA are traded daily?: The average number of IPHA shares traded daily for last 3 months was 68.57K.
What is the market cap of IPHA currently?: The market value of IPHA currently stands at $164.33M with its latest stock price at $1.75

Enter your email address below for free access to our Innate Pharma S.A. (IPHA) research center and poll results.

Innate Pharma S.A.

$1.75 USD

Company Overview

Liquidity Metrics

Sales & Valuation

Profitability

P/E Metrics

Analyst Price Target & Rating

Poll Results